Superworth

OmniAb revenue OABI

Sales by quarter and over the last twelve months, from 2022.

Last 12 months, to Sep 30, 2026
$40.2M
Latest quarter, Q3 FY26
$4M
+78% on a year earlier
Fiscal year 2025
$18.7M
−29% on the year before

OmniAb's revenue was $40.2M over the twelve months to Sep 30, 2026, up 91% on a year earlier.

In its latest quarter, Q3 FY26, it was $4M, up 78% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$18.7M−29%
FY2024$26.4M−23%
FY2023$34.2M−42%
FY2022$59.1Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q3 FY26$4M+78%$40.2M
Q2 FY26$13.4M+244%$38.5M
Q1 FY26$14.4M+247%$28.9M
Q4 FY25$8.4M−22%$18.7M
Q3 FY25$2.2M−46%$21.1M
Q2 FY25$3.9M−49%$23M
Q1 FY25$4.2M+9%$26.7M
Q4 FY24$10.8M+124%$26.4M
Q3 FY24$4.2M−24%$20.4M
Q2 FY24$7.6M+10%$21.7M
Q1 FY24$3.8M−78%$21M
Q4 FY23$4.8M−86%$34.2M

Against its peers

Companies in Medical - Diagnostics & Research nearest OmniAb's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
OABIOmniAb$40.2M+91% a year
NRCNRC Health$140M−0% a year
VCYTVeracyte$561.9M+17% a year
CDNACareDx$497.4M+39% a year
BLLNBillionToOne$397.4M+90% a year
ICCCImmucell$30.7M+8% a year
LNTHLantheus$1.6B+2% a year
Peer median$447.4M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on OmniAb

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.